Novartis Cancer Unit To Pay $8M To Settle Securities Row
Novartis AG subsidiary Genoptix Inc. will pay nearly $8 million to end a putative securities class action alleging the company misrepresented customer demand for diagnostic cancer testing and didn't disclose factors...To view the full article, register now.
Already a subscriber? Click here to view full article